Assignee
SHANDONG BOAN BIOTECHNOLOGY CO LTD
CN·6 granted patents·6 pending applications·1 citations·filing 2020–2023
Top patents by PatentIndex Score
12 records- 0174US12492252B2Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibodySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Granted Dec 9, 2025·1 cites·20 claims
- 0259US2025121082A1Anti-cd228 antibody and drug conjugate thereofSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
- 0357US12325751B2Anti-CD25 antibody and application thereofSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted Jun 10, 2025·0 cites·14 claims
- 0457US2024336903A1Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling PathwaySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 0556US2023355764A1Downregulation of membrane-bound proteins by receptor tac technologySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0656US2023272040A1Stealth chimeric antigen receptor and use thereof in reducing cytotoxicity towards normal cellsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0750US2024342283A1ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of TumorsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 0846US12325748B2Bifunctional fusion protein against PDL1 and TGFβ and use thereofSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted Jun 10, 2025·0 cites·6 claims
- 0946US2024117035A1Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumorsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 1044US12338288B2Interleukin-4 receptor antibody and application thereofSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted Jun 24, 2025·0 cites·9 claims
- 1143US12312402B2Antibody or chimeric antigen receptor which targets Claudin 18.2SHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted May 27, 2025·0 cites·20 claims
- 1241US12545730B2Optimized anti-CD3 arm in the generation of t-cell bispecific antibodies for immunotherapySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted Feb 10, 2026·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when SHANDONG BOAN BIOTECHNOLOGY CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →